论文部分内容阅读
目的：比较降纤酶与川芎嗪治疗急性缺血性脑血管疾病（ＡＩＣＤ）的疗效。方法：降纤酶组３２例（男性１７例，女性１５例；年龄５９±ｓ９ａ）用降纤酶１０ＩＵ加入０．９％氯化钠注射液２５０ｍＬｉｖ，ｄｒｉｐ，ｑｄ×３ｄ，ｄ４剂量减半，ｉｖ，ｄｒｉｐ，ｑｄ×３ｄ，均于１～１．５ｈ滴完。川芎嗪组３１例（男性１７例，女性１４例；年龄５７±８ａ）用川芎嗪２００ｍｇ加入０．９％氯化钠注射液２５０ｍＬ静滴×１２ｄ。结果：降纤酶组与川芎嗪组总有效率分别为９７％与８１％（Ｐ＜０．０１）；血小板聚集率、血液粘度２组均有显著下降，凝血因子Ｉ与血脂仅降纤酶组有显著下降（Ｐ＜０．０５或Ｐ＜０．０１），２组均无严重不良反应。结论：降纤酶治疗ＡＩＣＤ明显优于川芎嗪
Objective: To compare the efficacy of defibrase and ligustrazine in the treatment of acute ischemic cerebrovascular disease (AICD). Methods: 32 patients (17 males and 15 females; age 59 ± s9a) were treated with defibrase 10IU, 0.9% sodium chloride injection 250mLiv, drip, qd × 3d, d4 dose reduced by half, iv, drip, qd × 3d, all in 1 ~ 1.5h drops finished. Ligustrazine group of 31 patients (17 males and 14 females; age 57 ± 8a) with ligustrazine 200mg 0.9% sodium chloride injection 250mL intravenous infusion × 12d. Results: The total effective rate of defibrase group and ligustrazine group was 97% and 81%, respectively (P <0.01), and the platelet aggregation rate and blood viscosity decreased significantly Group had a significant decline (P <0.05 or P <0.01), two groups were no serious adverse reactions. Conclusion: Defibrase treatment AICD was significantly better than ligustrazine